Effect of pentoxifilin on nephrotic range proteinuria in glomerulopathies and chronic allograft nephropathy.: Results of 6 months treatment

The proteinuria has been considered as an expresion of damage or disfunction of glomerular permeability. The proinflamatory cytokines play an essential role in the development of this damage. Pentoxifillyne (PTX) is an inhibitor of phosphodiesterase and have an antiinflamatory as well as inmunomodulator effect. This study assessed the efficiency of PTX to reduce the proteinuria of nephrotic type in a group of patients with primary glomerulophaties, diabetes and chronic allograft nephropathy (CAN). Seventeen adult patients, with proteinuria >= to 3.5 gr/24 hs and a glomerular filtration rate >= to 25 ml/min (MDRD) were trated with 400 mg of PTX twice a day during 6 months, without leaving the previous treatment. Laboratory results were compared before the treatment and 6 months after. There was an significant decrease of proteinuria (p=0.0006) as well as a remarkable increase of serum albumina (p= 0.0002). There were no modifications as regards the renal function and besides, cholesterol and trigliceryds levels improved. In conclusion, 800 mg/day of PTX is harmless, sure and effective to reduce the proteinuria in glomerulopathies and CAN, despite the renal function degree.